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PERIPHERAL BLOOD STEM CELLS AND GRANULOCYTE COLONY-STIMU-
LATING FACTOR ARE ASSOCIATED WITH ACUTE GRAFT-VERSUS-HOST
DISEASE
Ringden, O., Remberger, M. Karolinska Institutet, Karolinska University
Hospital Huddinge, Stockholm, Sweden
Does granulocyte colony-stimulating factor (G-CSF) increases
GVHD or not? A mouse model of GVHD showed that G-CSF in-
duce GVHD after bone marrow (BM) transplantation (Morris et al,
Nature Med 15:436, 2009). Total body irradiation (TBI) increased
G-CSF receptors on host dendritic cells, stimulating acute GVHD.
Their report prompted us to reassess the role of G-CSF prophy-
laxis in our HSCT patients. During 1994–2002, 260 patients
were given G-CSF prophylaxis. Patients not given G-CSF
(n5 205) who underwent HSCT from 1993 to 2003 were controls.
We included all patients receiving BM (n5 286) or peripheral
blood stem cell (PBSC) grafts (n5 179) from HLA-identical sib-
lings (n5 225) or HLA-A, -B, or DRß1 genomically identical un-
related donors (MUDs; n5 240). The G-CSF group had more
MUD transplants, fewer patients receiving reduced-intensity con-
ditioning (RIC), more patients receiving antithymocyte globulin
(p\0.001), and AB0 mismatch was commoner (p5 0.03). Patients
treated with G-CSF had acute GVHD (grades II–IV) of 29%, vs.
19% in the controls (p\0.01). GVHD occurred in 33% of pa-
tients given PBSC, as compared to 19% of those given BM
(p\0.001). There was no significant difference in incidence of
GVHD between HLA-identical sibling transplants and MUD
transplants, between those with myeloablative conditioning and
those with RIC, or between those treated with TBI and chemother-
apy and those treated with chemotherapy only. In patients condi-
tioned with chemotherapy, 34% in the G-CSF group developed
acute GVHD as compared to 21% in the controls (p5 0.035). In
patients treated with TBI, those given G-CSF had an incidence
of acute GVHD (grades II–IV) of 26% as opposed to 17% in the
controls (p5 0.10). In PBSC recipients, 39% in the G-CSF group
developed acute GVHD as compared to 24% in the controls
(p5 0.025). In recipients of BM, the corresponding figures were
22% and 15%, respectively, in the two groups (p5 0.19). In the
present study, a multivariate analysis showed that acute GVHD
of grades II–IV was associated with PBSC grafting (hazards ratio
(HR)5 2.29, p\0.0001), female donors (HR5 1.74, p5 0.005),
major AB0 mismatch (HR5 1.58, p5 0.03), and
G-CSF (HR5 1.52, p5 0.03). Differences were adjusted. There
were no differences between the two groups regarding non-relapse
mortality, relapse, and survival.
Conclusion: G-CSF induces GVHD in mice, but differs compared
to humans regarding the role of source of stem cell and conditioning
regimen.404
SIROLIMUS, TACROLIMUS, AND RABBIT ATG (RATG) AS GRAFT-VERSUS-
HOST PROPHYLAXIS IN PATIENTS UNDERGOING UNRELATED DONOR
HEMATOPOIETIC STEM CELL TRANSPLANT (HCT)
Khaled, S.K., Palmer, J., Parker, P., Nademanee, A., Pullarkat, V.,
Cai, J.-L., Snyder, D., Karanes, C., Senitzer, D., Forman, S.,
Nakamura, R. City of Hope, Duarte, CA
The use of sirolimus combined with tacrolimus +/- low-dose
methotrexate (MTX) recently showed a promising result in pre-
venting acute GVHD after unrelated donor HCT (Antin et al.
Blood 2003) although a significant number of patients still experi-
enced chronic GVHD. In an attempt to further improve the out-
come, we have developed a novel combination of tacrolimus (FK),
sirolimus (SIR) and r-ATG +/- MTX (MTX given for patients
with a mismatch donor) and studied in a total of 51 patients
who underwent unrelated donor HCT from 7/5/2006 to 7/31/2009. The median age at transplant was 56 (range: 16 -71).
Twenty were female and 31 were male. Indications for transplant
were as follows: ALL (n5 12, CR1/25 11, Induction Failure5 1),
AML (n5 19: CR1/25 12: relapse/induction failure5 7), CML
(n5 4: CP1/25 2, AP/BC5 2), non-Hodgkin Lymphoma
(n5 5); CLL (n5 1), MDS (n5 8), MPD (n5 2). Thirty one pa-
tients received reduced-intensity conditioning (fludarbine/melpha-
lan [Flu/Mel]) and 20 received full-intensity conditioning (FTBI/
VP-16: n5 13, FTBI/Cytoxan: n5 7). All received PBSC graft ex-
cept for two patients who received bone marrow graft. Twenty-
nine of 51 patients had a 10/10-match donor by high resolution
HLA typing. Engraftment rate was 92.2% (n5 47) with the me-
dian neutrophil engaftment at 15 days (range: 10-39). Eighteen
patients (38% of 47 engrafted) developed grade II-IV acute
GVHD (grade III5 3, grade IV5 0). Chronic GVHD developed
in 21 of 37 evaluable patients (57%, limited n5 7, extensive
n5 14). We observed TTP/HUS in 10 patients (20%) and one
case of VOD. Eighteen (42%) of 43 patients at risk (R+ or D+)
developed CMV reactivation, while 10 patients developed EBV re-
activation (19.6%). After a median follow up of 11 months (range:
2-35) 38 patients were alive. The 1-year probabilities of overall
survival, disease-free survival (DFS), and relapse rate were 74.7%
(63-83%), 73.2% (62-82%), and 11% (5-25%), respectively.
Non-relapse mortality was 14.7% (8-26%) at 100 day and
17.5% (10-29%) at 1 year. There were no significant differences
in the outcomes according to conditioning regimens, although
there was a trend for lower NRM with Flu/Mel (11% vs. 27%
at 1 year, p5 0.1).
In summary FK/SIR combined with r-ATG +/- MTX is associ-
ated with a promising early result in GVHD prevention and survival
in this high-risk population. However, the rate of graft failure (n5 4)
appeared greater than our historic data, which is being further inves-
tigated at our institution.405
PROGRESSIVE IMPROVEMENT IN STEROID-REFRACTORY/DEPENDENT/
INTOLERANT CUTANEOUS CHRONIC GRAFT-VERSUS-HOST DISEASE
(CGVHD) FOLLOWING A 24-WEEK COURSE OF EXTRACORPOREAL
PHOTOPHERESIS (ECP)
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In a previously reported multicenter randomized standard-ther-
apy controlled trial, a 12-week course of ECP resulted in several
beneficial outcomes in patients (pts) with steroid-refractory/intol-
erant/dependent cGVHD. (Flowers et al, Blood 112:2667-74.
2008). We conducted an open-label cross-over extension study
to provide access to ECP for participants in the standard of care
arm of this randomized study and enrolled 29 pts. ECP was ad-
ministered 3 times during week 1, 2 treatments weekly until
week 12 then 2 treatments until week 24. The median age of the
study cohort was 43 (20-67) years and 26 pts (90%) had extensive
cGVHD. Onset was de novo in 11 (37.9%), progressive in 15
(51.7%) and quiescent in 3 (10.3%). Twenty-five of 29 pts
(86%) completed the 24 week course of ECP open-label treat-
ment. Causes for not completing the 24-weeks were GVHD pro-
gression (n5 2), 1 suicide, and 1 withdrawal of consent. Mean
daily steroid dose was 18.4 mg at the first ECP visit in this exten-
sion study (baseline). The median total skin score (TSS) was 7.8
(1.0-18.5) at the start of this cross-over extension study. The me-
dian percent change in TSS from baseline to week 12 and week 24
was -8.0 and -22.7, respectively. Four pts (14%) and 7 pts (24%)
achieved a $50% reduction in steroid dose at weeks 12 and 24, re-
spectively. In 4 pts (14%) and 8 pts (28%) a $50% reduction in
steroid dose and a final steroid dose of\10 mg/day at weeks 12
and 24 was obtained respectively. Complete or partial skin
response at week 24 was observed in 4 pts (14%) by investigator
assessment.
